N eisseria gonorrhoeae has developed resistance to multiple antimicrobials that were previously recommended for treatment, including penicillin, tetracycline, and ciprofloxacin (1). Currently, the only recommended treatment for gonorrhea in Europe and the United States is dual treatment with ceftriaxone and azithromycin (2, 3). However, decreases in susceptibilities to cephalosporins (4-7) and reports of cefixime and ceftriaxone treatment failures worldwide (8-10) indicate that the emergence of cephalosporin-resistant gonorrhea could be imminent. Because there are limited remaining effective therapeutic options for gonorrhea (11, 12), ceftriaxone resistance in N. gonorrhoeae would present significant challenges for individual case management and gonorrhea control in the community. As a result, surveillance of antimicrobial susceptibilities among N. gonorrhoeae strains will be increasingly critical to inform gonorrhea treatment recommendations.
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N. gonorrhoeae can infect the urogenital tract, rectum, and pharynx through sexual contact, and infection at extragenital sites may facilitate the acquisition or development of resistance mutations. Rectal infection and exposure to fecal lipids provide selective pressure for mutations such as those in the mtr locus, which confer resistance to hydrophobic molecules and drugs (13) (14) (15) (16) . Pharyngeal infection supplies the opportunity for genetic reassortment between N. gonorrhoeae and other Neisseria species that colonize the pharynx (17, 18) . Specifically, the mosaic penA allele, a key genetic determinant associated with decreased cephalosporin susceptibility, appears to have evolved through recombination with penA genes from commensal Neisseria species (18) (19) (20) . In addition, pharyngeal infections are more difficult to eradicate than urogenital or rectal infections (21, 22) and are typically asymptomatic, which may provide an optimal setting for selection of resistance mutations. It is notable that the first identified N. gonorrhoeae strain with high-level resistance to ceftriaxone was isolated from the pharynx (8) . Furthermore, high rates of resistance and elevated MICs are frequently observed among gay men, bisexual men, and other men who have sex with men (MSM) (7, 23) , among whom extragenital infections are common (24) (25) (26) .
Globally, surveillance for N. gonorrhoeae antimicrobial susceptibilities is conducted mostly with urogenital isolates (5, 6, 27) , and there are few published data comparing the susceptibilities of urogenital, rectal, and pharyngeal isolates. Although some reports suggested that rectal isolates or pharyngeal isolates are less susceptible than urethral isolates (14, 28, 29) , those evaluations did not control for the sex of sex partners, which potentially confounded the association of anatomic site with antimicrobial susceptibility. In the United States, the Centers for Disease Control and Prevention (CDC) Gonococcal Isolate Surveillance Project (GISP) monitors susceptibility trends exclusively among urethral isolates obtained from symptomatic men (30) . Because the CDC relies on GISP data in producing gonorrhea treatment guidelines, including treatment recommendations for extragenital infections, it is important to ascertain whether the susceptibilities of urethral isolates differ from those of isolates from pharyngeal or rectal infections. The objectives of this analysis were to describe the antimicrobial susceptibilities of urethral, rectal, and pharyngeal isolates obtained from MSM and to determine whether antimicrobial susceptibilities differed according to anatomic site.
MATERIALS AND METHODS
Study group and isolate collection. Demographic data and N. gonorrhoeae isolates were collected from MSM attending five sexually transmitted disease (STD)/sexual health clinics throughout the United States. Clinics were located in five jurisdictions (state or local health departments) that participated in the STD Surveillance Network (SSuN), i.e., Chicago, Illinois; Los Angeles, California; New York, New York; Philadelphia, Pennsylvania; and Seattle, Washington. The SSuN is a sentinel site surveillance network that collects demographic, behavioral, and clinical data from persons attending STD/sexual health clinics. For this evaluation, MSM were defined as men who reported having had sex with at least one male partner or who self-identified as gay, bisexual, or homosexual. Between December 2011 and September 2013, specimens for N. gonorrhoeae culture and antimicrobial susceptibility testing were collected from (i) MSM who presented with urethral symptoms consistent with N. gonorrhoeae infections, (ii) MSM who reported sexual contact with a N. gonorrhoeae-infected partner, and (iii) MSM with N. gonorrhoeae infections that had been identified by screening using a nonculture test (e.g., nucleic acid amplification test [NAAT]) who had not yet received treatment. Among MSM who met at least one of these criteria, pharyngeal and rectal cultures were collected from individuals who reported exposure at those sites. Urethral cultures were collected only from MSM with urethral symptoms. Because the data were collected through disease surveillance activity, this activity was determined not to be human subjects research and was approved by the CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Clinics that had implemented NAATbased screening for N. gonorrhoeae continued to screen and to test for N. gonorrhoeae according to clinic protocols. MSM diagnosed with N. gonorrhoeae infections were treated according to routine standards of care.
Laboratory procedures. At local clinics and/or laboratories, specimens for N. gonorrhoeae isolation were inoculated onto selective media and incubated at 35°C in 5% CO 2 . Presumptive N. gonorrhoeae isolates were confirmed by local laboratories according to their standard protocols. Gonococcal isolates were subcultured on supplemented chocolate medium, frozen in trypticase soy broth with 20% glycerol, and shipped monthly to one of two participating GISP reference laboratories (30) .
Reference laboratories performed confirmatory tests on all isolates, to verify the isolation of N. gonorrhoeae, and determined the antimicrobial susceptibilities of all isolates using agar dilution methods. Standardized bacterial suspensions were inoculated on Difco GC medium base supplemented with 1% IsoVitalex Enrichment supplement (Becton Dickinson Diagnostic Systems, Sparks, MD). Antimicrobials tested included azithromycin (in the range of 0.03 g/ml to 2 g/ml at one laboratory and the range of 0.03 g/ml to 16 g/ml at the second laboratory), cefixime (0.015 g/ml to 2 g/ml), ceftriaxone (0.008 g/ml to 2 g/ml), ciprofloxacin (0.015 g/ml to 16 g/ml), penicillin (0.25 g/ml to 16 g/ml), and tetracycline (0.25 g/ml to 16 g/ml). Isolates found to have cefixime or ceftriaxone MICs of Ն0.5 g/ml were tested to the endpoint at the reference laboratories. One laboratory shipped isolates with azithromycin MICs of Ն2 g/ml to the CDC, and the MIC endpoints obtained by the CDC were used for analysis. At the second laboratory, isolates found to have azithromycin MICs of Ն16 g/ml were tested to the endpoint at that laboratory. All isolates were tested for ␤-lactamase activity using the nitrocefin test. As described by the GISP protocol (30) , isolates with azithromycin MICs of Ն2 g/ml, cefixime MICs of Ն0.25 g/ml, or ceftriaxone MICs of Ն0.125 g/ml were shipped to the CDC for confirmation. To ensure the accuracy of susceptibility results, control N. gonorrhoeae strains with known MICs were included with each susceptibility test run. For additional quality assurance, reference laboratories tested a panel of 15 unidentified N. gonorrhoeae strains (provided by the CDC) twice yearly.
Interpretation of susceptibility results. MIC data were interpreted according to criteria recommended by the Clinical and Laboratory Standards Institute (CLSI) for ciprofloxacin resistance (MIC of Ն1 g/ml), penicillin resistance (MIC of Ն2 g/ml or ␤-lactamase positive), and tetracycline resistance (MIC of Ն2 g/ml) (31). Because CLSI has not established criteria for resistance to azithromycin, cefixime, or ceftriaxone, we used breakpoints described in the GISP protocol (30) (azithromycin MIC of Ն2 g/ml, cefixime MIC of Ն0.25 g/ml, and ceftriaxone MIC of Ն0.125 g/ml) as the definitions of "elevated MICs" for these antimicrobials.
Statistical analyses. We used the chi-square statistic to compare frequency distributions of categorical variables (city, age group, race/ethnicity, and HIV status) according to anatomic site. To assess antimicrobial susceptibilities according to anatomic site of infection, we compared (i) the proportions of isolates with elevated MICs or resistance and (ii) the geometric mean MIC for each antimicrobial according to anatomic site. Because of differences in susceptibilities according to geographic location (23, 27) , geographic location was treated as a confounder and all analyses were adjusted for city as an independent variable. To calculate geometric mean MICs, we converted MICs from an exponential scale to a linear scale by taking the logarithm of the MICs. Our analytic sample included isolates obtained from MSM with concurrent infections at multiple anatomic sites. MICs for isolates from different anatomic sites from the same person could be correlated, resulting in a lack of independence among observations. To take this correlation into account, we applied generalized linear models to the log-transformed data by using the generalized estimating equations method to test for differences between anatomical sites. The proportions of isolates with elevated MICs or resistance were also compared according to anatomic site using these models. Adjustments for multiple comparisons between sites were made with the Tukey-Kramer method. P values of Ͻ0.05 were used to indicate significant differences. All statistical analyses were conducted using SAS (version 9.3; SAS Institute, Cary, NC).
Analysis of paired isolates from MSM with concurrent infections. We identified paired isolates that were obtained from MSM with concurrent pharyngeal and urethral infections or concurrent rectal and urethral infections. For these pairs, we compared urethral isolate MICs and extragenital isolate MICs and described the proportions of pairs with discordant MICs (differing by Ն2 doubling dilutions). For cases with discordant MICs, we assessed the proportion with a higher urethral MIC than extragenital MIC and the proportion with a higher extragenital MIC than urethral MIC.
RESULTS

Sources of tested isolates.
In total, 205 pharyngeal, 261 rectal, and 976 urethral isolates were obtained from MSM during the study period of December 2011 through September 2013. The geographic distributions of isolates varied according to anatomic site (Table 1) . Almost one-half of pharyngeal isolates were collected in Seattle (49.3%), and the majority of rectal isolates were collected in either Seattle (41.0%) or New York City (34.1%). In contrast, the geographic distribution of urethral isolates was more even, with the greatest proportion of isolates collected in New York City (37.2%). The ages and races/ethnicities of MSM from whom isolates were collected also differed according to anatomic site. MSM in the youngest age category (ages of 16 to 25 years) accounted for a greater proportion of rectal isolates (51.0%) than pharyngeal (39.0%) or urethral (32.9%) isolates. White MSM accounted for the majority of pharyngeal (60.2%) and rectal (55.5%) isolates but a smaller proportion of urethral isolates (46.7%). MSM HIV status did not differ significantly according to anatomic site of infection.
Comparison of antimicrobial susceptibilities according to anatomic site. The MIC distributions for pharyngeal, rectal, and urethral isolates for each antimicrobial are presented in Fig. 1 . The proportions of pharyngeal and rectal isolates with elevated MICs did not differ from the proportions of urethral isolates with elevated MICs for azithromycin, cefixime, or ceftriaxone (Table 2) . Overall, 1.2% of urethral isolates had elevated azithromycin MICs (Ն2 g/ml), compared with 2.0% of pharyngeal isolates (cityadjusted odds ratio [aOR], 2.2 [95% confidence interval {CI}, 0.6 to 8.5]) and 1.5% of rectal isolates (aOR, 1.6 [95% CI, 0.4 to 6.0]). For cefixime, 3.0% of urethral isolates had elevated MICs (Ն0.25 g/ml), compared with 1.5% of pharyngeal isolates (aOR, 0.8 [95% CI, 0.2 to 3.2]) and 4.2% of rectal isolates (aOR, 1.6 [95% CI, 0.7 to 3.9]). For ceftriaxone, 1.7% of urethral isolates had elevated MICs (Ն0.125 g/ml), compared with 0.5% of pharyngeal isolates (aOR, 0.4 [95% CI, 0.0 to 3.9]) and 1.5% of rectal isolates (aOR, 0.9 [95% CI, 0.2 to 4.2]). The proportions of pharyngeal isolates with elevated azithromycin, cefixime, or ceftriaxone MICs did not differ from the proportions of rectal isolates with elevated MICs (data not shown). Similarly, there were no significant differences in the proportions of isolates resistant to ciprofloxacin, penicillin, or tetracycline according to anatomic site in the cityadjusted analysis.
City-adjusted geometric mean MICs for azithromycin, ceftriaxone, ciprofloxacin, penicillin, or tetracycline did not differ according to anatomic site (Table 3) . For cefixime, the city-adjusted geometric mean MIC for rectal isolates was significantly higher than that for pharyngeal isolates (ratio of city-adjusted geometric means, 1.17 [95% CI, 1.01 to 1.37]). However, neither the pharyngeal mean MIC nor the rectal mean MIC differed significantly from the urethral geometric mean MIC.
Analysis of paired isolates from MSM with concurrent infections. Paired pharyngeal and urethral isolates were obtained from 55 MSM with concurrent pharyngeal and urethral gonococcal infections (Table 4) . Paired rectal and urethral isolates were obtained from 45 MSM with concurrent rectal and urethral infections (Table 5 ). These pairs included isolates from 12 MSM with concurrent infections at all three anatomic sites. Overall, Ͼ90% of pharyngeal-urethral pairs and Ͼ88% of rectal-urethral pairs had concordant MICs (identical MICs or MICs within 1 dilution of each other) for each antimicrobial tested. Although the absolute numbers of pairs with discordant MICs (Ն2-dilution differences) were small, the proportion of pairs with a higher urethral MIC than extragenital MIC was similar to the proportion with a higher extragenital MIC than urethral MIC when discordance was observed. There was no trend toward either pharyngeal or rectal isolates having higher MICs than urethral MICs among MSM with concurrent pharyngeal and urethral or rectal and urethral infections.
DISCUSSION
In this multicity analysis of gonococcal isolates collected from MSM, we found no evidence that MICs of isolates obtained from extragenital sites were higher than those of isolates obtained from the urethral site. We found relatively high prevalences of elevated azithromycin MICs (1.2% to 2.0%), elevated cefixime MICs (1.5% to 4.2%), and elevated ceftriaxone MICs (0.5% to 1.7%). We also found high prevalences of resistance to antimicrobials previously recommended for gonorrhea treatment, i.e., ciprofloxacin (32.2% to 37.6%), penicillin (18.1% to 26.1%), and tetracycline (37.6% to 44.8%). These data are consistent with GISP reports of gonococcal susceptibilities among MSM during the same time period (27, 32) and underscore the importance of identifying new antimicrobial options for gonorrhea treatment, given the potential threat of resistance to cephalosporins. The proportions of isolates with elevated azithromycin, cefixime, or ceftriaxone MICs or with resistance to ciprofloxacin, penicillin, or tetracycline did not differ according to anatomic site. In addition, neither pharyngeal nor rectal isolate geometric mean MICs differed significantly from those of urethral isolates. For each antimicrobial tested, pharyngeal, rectal, and urethral geometric mean MICs were within 1 dilution of each other. These findings differ from the recent report by Hottes et al. (28) that the prevalences of elevated azithromycin, cefixime, and ceftriaxone MICs were consistently higher among rectal and pharyngeal isolates than among urethral isolates. As Hottes et al. noted, however, they were unable to control for the sex of sex partners, which likely confounded the results. GISP isolates from MSM are more likely than isolates from men who have sex only with women to exhibit elevated MICs and resistance (23) . Consequently, the higher prevalences of elevated MICs among extragenital isolates versus urethral isolates in the report by Hottes et al. (28) likely reflected the higher prevalences among N. gonorrhoeae strains circulating within MSM sexual networks versus heterosexual networks. Our data indicate that, among MSM, extragenital isolates are not more likely than urethral isolates to have elevated MICs or resistance.
This finding has implications for the surveillance of N. gonorrhoeae antimicrobial susceptibilities, as well as the use of surveillance data to inform treatment guidelines, including treatment recommendations for pharyngeal and rectal infections. The U.S. surveillance system for N. gonorrhoeae antimicrobial susceptibilities, GISP, monitors susceptibility trends exclusively among urethral isolates obtained from symptomatic men (30) . This sampling strategy is an efficient means of conducting surveillance of gonococcal susceptibilities in settings in which gonococcal culture, which is required for antimicrobial susceptibility testing, has largely been replaced by NAATs for routine diagnosis of gonorrhea. Male urogenital N. gonorrhoeae infections are easier to identify because they are typically symptomatic, whereas pharyngeal, rectal, and female urogenital infections are typically asymptom-atic. Additionally, the sensitivity of gonococcal culture is higher for the urethral site than for other sites (33) (34) (35) . Men with urethral symptoms also represent a consistent population likely to seek clinical evaluation and less likely to be affected by changes in screening practices, which provides additional advantages for surveillance systems that monitor susceptibility trends over time. Our results suggest that surveillance of gonococcal antimicrobial susceptibilities based on urethral isolates from MSM adequately represents the susceptibilities of N. gonorrhoeae strains circulating among MSM, supporting the GISP sampling strategy.
Our analysis also compared the MICs of paired isolates collected from MSM with concurrent urethral and extragenital gonococcal infections, and it found that, depending on the antimicrobial, 2% to 11% of pairs had discordant MICs that differed by Ն2 dilutions. Within these discordant pairs, there was no apparent association between anatomic site and the higher MIC. Concurrent infections at multiple anatomic sites with different strains of N. gonorrhoeae that exhibited different antimicrobial susceptibilities were reported previously (36, 37) . These cases could represent separate infection events (i.e., infections at different anatomic sites with different strains), simultaneous infections with the same strain at different anatomic sites but subsequent mutation, or si- This analysis has several limitations. These data do not exclude the possibility that pharyngeal or rectal gonococcal infections facilitate development of antimicrobial resistance. It is possible that gonococcal resistance emerges first at extragenital sites but is rapidly transmitted to other anatomic sites within sexual networks, so that antimicrobial susceptibilities do not differ according to anatomic site at the population level. A second limitation is that the sensitivity of gonococcal culture is lower for extragenital sites than for the urethra (33) (34) (35) , possibly due to the presence of other bacteria and differences in bacterial loads (38) . As a result, we obtained fewer pharyngeal and rectal isolates than urethral isolates. Additionally, in order to minimize discomfort, we limited the collection of urethral cultures to symptomatic men only, whereas extragenital cultures were obtained from eligible MSM regardless of symptoms. These two factors could potentially bias our findings, if growth in cultures or the presence of symptoms was associated with antimicrobial susceptibility. It is also possible that our study was insufficiently powered to detect small differences between anatomic sites; however, we observed no trend toward one site having consistently higher MICs than another. Finally, our data were limited to MSM, and it is possible that MICs differ according to anatomic site among other populations, such as women.
In conclusion, we found no evidence that extragenital N. gonorrhoeae isolates were less susceptible to antimicrobials than urethral isolates. At the population level, MICs for each antimicrobial were similar across anatomic sites, and the proportions of isolates with elevated MICs or resistance did not differ according to anatomic site. For individuals with concurrent N. gonorrhoeae infections at multiple anatomic sites, N. gonorrhoeae susceptibilities may be different at different sites, but no anatomic site was consistently less susceptible than another. Given the threat of cephalosporin resistance and the limited number of treatment options currently available, local surveillance of N. gonorrhoeae susceptibilities will become increasingly important for gonorrhea control programs. Our findings support the GISP strategy of monitoring susceptibilities among male urethral isolates to inform gonorrhea treatment guidelines.
